These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://adamimzq614913.ssnblog.com/37888443/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide